Does Socioeconomic Status Affect Disability Progression in MS?
Socioeconomic status has been linked to an elevated risk for disease progression in MS.
Multiple Sclerosis
NAIMS Summary on Emerging Techniques to Assess Neuroprotection and Repair in MS
Based on the collective opinion of the NAIMS Cooperative, there are a number of promising MRI techniques with different strengths and limitations to accelerate the discovery of effective treatments for all stages of multiple sclerosis.
AAN: No Increased MS Relapse Risk in Postpartum Period
Women with multiple sclerosis seem not to suffer from pregnancy-related relapses in the early postpartum period.
Prevalence of MS Increased Substantially From 1990 to 2016
Regions with the highest age-standardized multiple sclerosis prevalence estimates per 100,000 population included high-income North America, Western Europe, and Australasia.
Case Study: Headaches, Double Vision, and Tingling Extremities in a Young Woman
A 19-year-old woman with a history of migraine headaches initially presented with subacute onset of double vision and vertigo.The following case study was provided by Daniel Ontaneda, MD, and Marisa McGinley, DO, both neurologists at the Cleveland Clinic in Ohio. In addition, Dr Ontaneda is a co-primary investigator of the international Determining the Effectiveness of…
Managing Anxiety, Depression in Multiple Sclerosis Key to Mitigating Cognitive Effects of Disease
The management of symptoms of anxiety and of depression in patients with MS is key to mitigating their effect on cognition and functioning.
Atorvastatin Associated With Milder Disease Progression in Relapsing-Remitting Multiple Sclerosis
No significant associations were found between atorvastatin treatment and time to first relapse.
Contributors to Delay of Multiple Sclerosis Diagnosis ID’d
First symptoms and disease type are contributors to delays in multiple sclerosis diagnosis.
FDA to Review Diroximel Fumarate for Treatment of Relapsing Forms of MS
The FDA has accepted for review the New Drug Application for a novel oral fumarate candidate, diroximel fumarate, for the treatment of relapsing forms of multiple sclerosis.
Early Intensive Treatment May Improve Long-Term MS Outcomes
Long-term outcomes are more favorable for early intensive treatment versus first-line moderate-efficacy disease-modifying therapy in multiple sclerosis.
Next post in Multiple Sclerosis
